Drug Development

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's disease (AD) is characterized by neuroinflammation driven by microglial activation and inflammatory cytokines.
• Modulating microglial activity presents a promising therapeutic strategy for AD.
• Enrupatinib, a brain-penetrant CSF1R inhibitor, was investigated for its disease-modifying potential in AD mouse models.

Purpose of the Study:

• To evaluate the effects of enrupatinib on neuronal integrity and microglial responses in Alzheimer's disease models.
• To assess enrupatinib's impact on neuroinflammation, amyloid pathology, and cognitive function.

Main Methods:

• Utilized 5xFAD and J20 mouse models of Alzheimer's disease.
• Administered enrupatinib (300 mg/kg) and assessed cognitive function via Novel Object Recognition (NOR) and Y-maze tests.
• Analyzed microglia, amyloid plaques, and neuronal health using microscopy, immunofluorescence, qPCR, western blotting, and RNA sequencing.

Main Results:

• Enrupatinib therapy reduced neuroinflammatory markers and disease-associated microglia (DAM) gene expression.
• Observed a trend towards lower amyloid plaque deposition and significantly reduced neuronal fragmentation.
• Enrupatinib treatment enhanced cognitive performance in behavioral tests and downregulated inflammatory pathways.

Conclusions:

• Enrupatinib demonstrates significant potential in mitigating Alzheimer's disease pathologies.
• The drug effectively reduces neuroinflammation and preserves neuronal integrity.
• Enrupatinib represents a promising therapeutic candidate for Alzheimer's disease treatment.